ENDP - Endo International plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
5.63
-0.72 (-11.34%)
At close: 4:00PM EST

5.54 -0.09 (-1.60%)
After hours: 7:59PM EST

Stock chart is not supported by your current browser
Previous Close6.35
Open6.13
Bid5.54 x 21500
Ask5.56 x 2900
Day's Range5.61 - 6.17
52 Week Range1.97 - 12.49
Volume6,707,142
Avg. Volume7,028,404
Market Cap1.277B
Beta (5Y Monthly)1.46
PE Ratio (TTM)N/A
EPS (TTM)-1.88
Earnings DateMay 06, 2020 - May 10, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.89
  • Endo's (ENDP) Earnings & Revenues Trump Estimates in Q4
    Zacks

    Endo's (ENDP) Earnings & Revenues Trump Estimates in Q4

    Endo (ENDP) earnings and sales beat estimates in the fourth quarter but witness year-over-year declines.

  • Thomson Reuters StreetEvents

    Edited Transcript of ENDP earnings conference call or presentation 26-Feb-20 1:00pm GMT

    Q4 2019 Endo International PLC Earnings Call

  • Endo International (ENDP) Q4 Earnings and Revenues Top Estimates
    Zacks

    Endo International (ENDP) Q4 Earnings and Revenues Top Estimates

    Endo (ENDP) delivered earnings and revenue surprises of 29.82% and 5.25%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

  • PR Newswire

    Endo Reports Fourth-Quarter And Full-Year 2019 Financial Results

    Endo International plc (NASDAQ: ENDP) today reported financial results for the fourth quarter and full year ended December 31, 2019.

  • ACCESSWIRE

    Endo International plc to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / February 26, 2020 / Endo International plc (NASDAQ:ENDP) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on February 26, 2020 ...

  • Endo International chooses a familiar face to be new CEO
    American City Business Journals

    Endo International chooses a familiar face to be new CEO

    Endo International has found its new president and chief executive officer in-house. The Dublin, Ireland-based pharmaceutical company, which has its U.S. headquarters in Malvern, said Blaise Coleman will take over as CEO effective March 6. Coleman has served as executive vice president and chief financial officer at Endo (NASDAQ: ENDP) since 2016.

  • Endo Names Blaise Coleman President and Chief Executive Officer
    CNW Group

    Endo Names Blaise Coleman President and Chief Executive Officer

    DUBLIN , Feb. 19, 2020 /CNW/ -- Endo International plc (ENDP) today announced that Blaise Coleman , who has served as the Company's Executive Vice President and Chief Financial Officer since 2016, will succeed Paul Campanelli as President and Chief Executive Officer and will become a member of the Board of Directors effective March 6, 2020 . Mr. Campanelli will continue to serve as Chairman of the Board. This appointment will complete the Chief Executive Officer succession plan that Endo announced in November 2019 .

  • Endo Appoints Mark G. Barberio to Board of Directors
    CNW Group

    Endo Appoints Mark G. Barberio to Board of Directors

    Endo Appoints Mark G. Barberio to Board of Directors

  • Earnings Preview: Endo International (ENDP) Q4 Earnings Expected to Decline
    Zacks

    Earnings Preview: Endo International (ENDP) Q4 Earnings Expected to Decline

    Endo (ENDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Small-Cap Healthcare ETF Outperforming in 2020: 5 Top Stocks
    Zacks

    Small-Cap Healthcare ETF Outperforming in 2020: 5 Top Stocks

    The small-cap healthcare companies are benefiting from the 2020 presidential election campaign, which has put pressure on the large cap cousins on how to overhaul the industry.

  • Here's Why You Should Add BioDelivery Stock to Your Portfolio
    Zacks

    Here's Why You Should Add BioDelivery Stock to Your Portfolio

    Here are five reasons which make BioDelivery (BDSI)) a good investment option in 2020.

  • CNW Group

    Endo Begins Shipment of Authorized Generic Version of Carafate® (sucralfate) Oral Suspension in the United States

    Endo Begins Shipment of Authorized Generic Version of Carafate® (sucralfate) Oral Suspension in the United States

  • PR Newswire

    Endo to Announce Fourth-Quarter and Full-Year 2019 Financial Results

    Endo International plc (NASDAQ: ENDP) will announce its fourth-quarter and full-year 2019 financial results on February 26, 2020 and members of its senior management team will host a conference call and webcast at 8:00am EST before the U.S. financial markets open.

  • J&J's $8B Jury Award in Risperdal Case Cut to $6.8M by Judge
    Zacks

    J&J's $8B Jury Award in Risperdal Case Cut to $6.8M by Judge

    A Philadelphia judge slashes J&J's (JNJ) punitive damages in a lawsuit, which claims that the company did not warm men that they could grow breasts by using its antipsychotic drug, Risperdal.

  • Endo reaches $8.75M opioid settlement with Oklahoma
    American City Business Journals

    Endo reaches $8.75M opioid settlement with Oklahoma

    Two Endo International Inc. subsidiaries have agreed to pay Oklahoma $8.75 million to resolve the state’s investigation into whether the pharmaceutical company had a role in the state’s opioid abuse crisis. The settlement agreement, under which the Endo business units admitted to no wrongdoing or liability, involved Endo Pharmaceuticals Inc. and Par Pharmaceuticals. Endo officials noted the amount it agreed to pay in connection with the settlement agreement is a "fraction" of the settlement and judgment amounts associated with other opioid manufacturers in Oklahoma.

  • Endo Up on Opioid Abuse Settlement Agreement With Oklahoma
    Zacks

    Endo Up on Opioid Abuse Settlement Agreement With Oklahoma

    Endo (ENDP) settles an ongoing opioid-abuse litigation issue with the state of Oklahoma for $8.75 million.

  • MarketWatch

    Endo settles opioid suit with Oklahoma AG

    Shares of Endo International Inc. are up 3% in afternoon trading on Friday after the company said it will pay $8.75 million to Oklahoma to settle allegations that it inappropriately promoted its opioids. As part of the settlement, the company did not admit wrongdoing. According to a news release from the Attorney General's office, Endo will not employ or contract with sales reps in Oklahoma and will not pay for direct or indirect promotion of opioids. Endo has also settled similar opioid-related lawsuits with two counties in Ohio. Endo's stock has tumbled 52% over the last year. The Health Care Select Sector SPDR exchange-traded fund is up 17%.

  • PR Newswire

    Endo Settles Opioid Investigation with State of Oklahoma for $8.75 million

    Endo International plc (NASDAQ: ENDP) today announced that its subsidiaries Endo Pharmaceuticals Inc. and Par Pharmaceutical, Inc. (collectively, the "Settling Parties") have executed a Settlement Agreement with the State of Oklahoma ("Oklahoma"). The Settlement Agreement fully and finally resolves Oklahoma's investigation of the Settling Parties in connection with the opioid abuse crisis in Oklahoma and includes a release of all associated claims by Oklahoma to the Settling Parties and all of their affiliated entities and persons (collectively, the "Endo Affiliates"). In connection with the Settlement Agreement, Endo Pharmaceuticals Inc. has agreed to pay $8.75 million to Oklahoma. The Settlement Agreement includes no admission of wrongdoing, fault or liability of any kind by the Endo Affiliates. The amount paid in connection with the Settlement Agreement is a fraction of the settlement and judgment amounts associated with other opioid manufacturers in Oklahoma to date and is the result of direct engagement among Oklahoma Attorney General Mike Hunter, his staff and counsel, and the Company's senior leadership.